ATRA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -124.62% compared to Atara Biotherapeutics, Inc.'s net margin of -255.85%. Atara Biotherapeutics, Inc.'s return on equity of -2818.48% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Atara Biotherapeutics, Inc. has a consensus price target of $19.00, signalling upside risk potential of 5.03%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.93%. Given that Atara Biotherapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Atara Biotherapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Atara Biotherapeutics, Inc. has a beta of -0.412, which suggesting that the stock is 141.173% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Atara Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Atara Biotherapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Atara Biotherapeutics, Inc. quarterly revenues are $3.5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Atara Biotherapeutics, Inc.'s net income of -$4.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Atara Biotherapeutics, Inc.'s price-to-earnings ratio is 8.25x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics, Inc. is 1.41x versus 10.96x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacira Biosciences, Inc. has a net margin of -124.62% compared to Atara Biotherapeutics, Inc.'s net margin of 3.03%. Atara Biotherapeutics, Inc.'s return on equity of -2818.48% beat Pacira Biosciences, Inc.'s return on equity of 2.81%.

Atara Biotherapeutics, Inc. has a consensus price target of $19.00, signalling upside risk potential of 5.03%. On the other hand Pacira Biosciences, Inc. has an analysts' consensus of $29.71 which suggests that it could grow by 14.82%. Given that Pacira Biosciences, Inc. has higher upside potential than Atara Biotherapeutics, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Atara Biotherapeutics, Inc..

Atara Biotherapeutics, Inc. has a beta of -0.412, which suggesting that the stock is 141.173% less volatile than S&P 500. In comparison Pacira Biosciences, Inc. has a beta of 0.224, suggesting its less volatile than the S&P 500 by 77.636%.

Atara Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacira Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics, Inc. pays -- of its earnings as a dividend. Pacira Biosciences, Inc. pays out -- of its earnings as a dividend.

Atara Biotherapeutics, Inc. quarterly revenues are $3.5M, which are smaller than Pacira Biosciences, Inc. quarterly revenues of $179.5M. Atara Biotherapeutics, Inc.'s net income of -$4.3M is lower than Pacira Biosciences, Inc.'s net income of $5.4M. Notably, Atara Biotherapeutics, Inc.'s price-to-earnings ratio is 8.25x while Pacira Biosciences, Inc.'s PE ratio is 58.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics, Inc. is 1.41x versus 1.67x for Pacira Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -124.62% compared to Atara Biotherapeutics, Inc.'s net margin of --. Atara Biotherapeutics, Inc.'s return on equity of -2818.48% beat Palatin Technologies's return on equity of --.

Atara Biotherapeutics, Inc. has a consensus price target of $19.00, signalling upside risk potential of 5.03%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Atara Biotherapeutics, Inc., analysts believe Palatin Technologies is more attractive than Atara Biotherapeutics, Inc..

Atara Biotherapeutics, Inc. has a beta of -0.412, which suggesting that the stock is 141.173% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Atara Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Atara Biotherapeutics, Inc. quarterly revenues are $3.5M, which are larger than Palatin Technologies quarterly revenues of --. Atara Biotherapeutics, Inc.'s net income of -$4.3M is higher than Palatin Technologies's net income of --. Notably, Atara Biotherapeutics, Inc.'s price-to-earnings ratio is 8.25x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics, Inc. is 1.41x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -124.62% compared to Atara Biotherapeutics, Inc.'s net margin of --. Atara Biotherapeutics, Inc.'s return on equity of -2818.48% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Atara Biotherapeutics, Inc. has a consensus price target of $19.00, signalling upside risk potential of 5.03%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3227%. Given that Theriva Biologics, Inc. has higher upside potential than Atara Biotherapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Atara Biotherapeutics, Inc..

Atara Biotherapeutics, Inc. has a beta of -0.412, which suggesting that the stock is 141.173% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.

Atara Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Atara Biotherapeutics, Inc. quarterly revenues are $3.5M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Atara Biotherapeutics, Inc.'s net income of -$4.3M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Atara Biotherapeutics, Inc.'s price-to-earnings ratio is 8.25x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics, Inc. is 1.41x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.